CLINICAL_TRIALS
trial_result
· 2015-03-19
Clinical Trial Update: A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035) [Phase 3]
Summary
Phase 3 trial evaluating a new formulation of RotaTeq in infants for immunogenicity, tolerability, and safety; completed with posted results in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Rotavirus Gastroenteritis | Phase 3 | Status: COMPLETED | Results posted: 2015-03-19